U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammation Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore…


Previous articleThe Wild World of 19th Century Psychedelics
Next articlePsychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board